Internal company documents that have emerged in a New Jersey trial make clear that marketing for Tylenol did not convey doctors’ concerns about its risks.
After an investigation, Canada’s top health agency considers whether to lower the maximum recommended daily dose of the active ingredient in Tylenol and other painkillers.